Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women ≥ 18 and ≤ 80 years old~* Subjects must be diagnosed with rheumatoid arthritis for at least 6 months before baseline~* Active RA defined as ≥ 6 swollen joints and ≥ 6 tender joints at screening and baseline and at least one of the following at screening:~  * erythrocyte sedimentation rate (ESR) ≥ 28 mm/hr~ * serum C-reactive protein (CRP) \> 1.0 mg/dL~* Subjects must be taking methotrexate (MTX) for ≥ 12 consecutive weeks and on a stable dose of MTX 7.5 to 25 mg/week for ≥ 8 weeks prior to receiving the investigational product (IP), and be willing to remain on a stable dose throughout the study~* Subject has no known history of active tuberculosis~Exclusion Criteria:~* Class IV RA, Felty's syndrome or history of prosthetic or native joint infection~* Major chronic inflammatory disease or connective tissue disease other than RA, with the exception of secondary Sjögren's syndrome~* Use of commercially available or investigational biologic therapies for RA as follows:~  * anakinra, etanercept within 1 month prior to first dose of IP~ * infliximab, abatacept, tocilizumab, golimumab, certolizumab within 3 months prior to first dose of IP~ * other experimental or commercially available biologic therapies for RA within 3 months or 5 half-lives (whichever is longer) prior to first dose of IP~* Previous receipt of rituximab or a biosimilar of rituximab~Other Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ABP 798 / ABP 798 (Type: EXPERIMENTAL): Participants received ABP 798 on days 1 and 15 (dose 1) and a second dose of ABP 798 at weeks 24 and 26 (dose 2). Each dose consisted of two 1000 mg intravenous infusions 2 weeks apart.
- Rituximab (US) / ABP 798 (Type: ACTIVE_COMPARATOR): Participants received rituximab (United States \[US\] formulation) on days 1 and 15 (dose 1) and transitioned to receive ABP 798 at weeks 24 and 26 (dose 2). Each dose consisted of two 1000 mg intravenous infusions 2 weeks apart.
- Rituximab (EU) / Rituximab (EU) (Type: ACTIVE_COMPARATOR): Participants received rituximab (European Union \[EU\] formulation) on days 1 and 15 (dose 1) and a second dose of rituximab (EU formulation) at weeks 24 and 26 (dose 2). Each dose consisted of two 1000 mg intravenous infusions 2 weeks apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).